HCPCS Level IIdrugActive
J0791
Inj crizanlizumab-tmca 5mg
BETOS: O1E
Effective: 2020-07-01
Referenced in 1 policies
Description
Injection, crizanlizumab-tmca, 5 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Adakveo
Manufacturer
Novartis Pharmaceuticals Corporation
HCPCS Dosage
5 MG
Billing Units
20.0000
1
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.